169 related articles for article (PubMed ID: 23619142)
1. Rosiglitazone is not associated with an increased risk of bladder cancer.
Tseng CH
Cancer Epidemiol; 2013 Aug; 37(4):385-9. PubMed ID: 23619142
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes.
Tseng CH
Ann Med; 2013 Dec; 45(8):539-44. PubMed ID: 24215589
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone does not affect the risk of ovarian cancer: analysis of a nationwide reimbursement database in Taiwan.
Tseng CH
Gynecol Oncol; 2013 Oct; 131(1):135-9. PubMed ID: 23877016
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone and oral cancer risk in patients with type 2 diabetes.
Tseng CH
Oral Oncol; 2014 Feb; 50(2):98-103. PubMed ID: 24239280
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese.
Tseng CH
BMC Cancer; 2015 Feb; 15():41. PubMed ID: 25655946
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus.
Tseng CH
Oncotarget; 2017 Jan; 8(2):3042-3048. PubMed ID: 27936468
[TBL] [Abstract][Full Text] [Related]
7. Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes.
Tseng CH
Acta Diabetol; 2014 Apr; 51(2):295-303. PubMed ID: 24509842
[TBL] [Abstract][Full Text] [Related]
8. Human insulin does not increase bladder cancer risk.
Tseng CH
PLoS One; 2014; 9(1):e86517. PubMed ID: 24466131
[TBL] [Abstract][Full Text] [Related]
9. Treatment with human insulin does not increase thyroid cancer risk in patients with type 2 diabetes.
Tseng CH
Eur J Clin Invest; 2014 Aug; 44(8):736-42. PubMed ID: 24931333
[TBL] [Abstract][Full Text] [Related]
10. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.
Chang CH; Lin JW; Wu LC; Lai MS; Chuang LM; Chan KA
Hepatology; 2012 May; 55(5):1462-72. PubMed ID: 22135104
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes.
Tseng CH
Metabolism; 2014 Aug; 63(8):1049-55. PubMed ID: 24889868
[TBL] [Abstract][Full Text] [Related]
12. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
Tseng CH
Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
[TBL] [Abstract][Full Text] [Related]
13. Prolonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes.
Tseng CH
BMC Cancer; 2015 Nov; 15():846. PubMed ID: 26537234
[TBL] [Abstract][Full Text] [Related]
14. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus.
Tseng CH
Diabetes Metab Res Rev; 2015 Sep; 31(6):619-26. PubMed ID: 25820555
[TBL] [Abstract][Full Text] [Related]
15. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan.
Tseng CH
BMC Cancer; 2013 Jan; 13():7. PubMed ID: 23286275
[TBL] [Abstract][Full Text] [Related]
16. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
17. The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.
Lee MY; Hsiao PJ; Yang YH; Lin KD; Shin SJ
PLoS One; 2014; 9(1):e85479. PubMed ID: 24427312
[TBL] [Abstract][Full Text] [Related]
18. Observational follow-up of the PROactive study: a 6-year update.
Erdmann E; Song E; Spanheimer R; van Troostenburg de Bruyn AR; Perez A
Diabetes Obes Metab; 2014 Jan; 16(1):63-74. PubMed ID: 23859428
[TBL] [Abstract][Full Text] [Related]
19. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
[TBL] [Abstract][Full Text] [Related]
20. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
